Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma.

9%, P = 0.002), and lymph-node metastases were reported in 62% in the nCT group and 35% in the nCRT group ( P = 0.001); moreover, survival analysis according to tumor histological type showed a trend towards improved survival among patients with squamous cell carcinoma receiving nCRT.

also in 53,322 other papers

Moreover, nCRT demonstrated a positive trend toward improved 3-year overall survival over nCT (47.4 vs. 27.7%), though that was not statistically significant ( P = 0.07).

also in 11,005 other papers